Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX53 plus Serplulimab and HLX04 in Untreated Advanced HCC
NCT06349980Phase 2Recruiting
- Sponsor
- Henlius
- Start
- Aug 2024
- Primary completion
- Feb 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of HLX53 in hepatocellular carcinoma (HCC), sponsored by Henlius. Started Aug 2024; status: recruiting.
02
Drugs
HLX53
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06349980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06349980.